Aarti Drugs Gelecekteki Büyüme

Future kriter kontrolleri 4/6

Aarti Drugs kazanç ve gelirin sırasıyla yıllık 31.5% ve 13.4% oranında artacağı tahmin edilmektedir. EPS'nin yıllık 31.5% oranında büyümesi beklenmektedir. Özkaynak kârlılığının 3 yıl içinde 17.7% olacağı tahmin edilmektedir.

Anahtar bilgiler

31.5%

Kazanç büyüme oranı

31.5%

EPS büyüme oranı

Pharmaceuticals kazanç büyümesi	17.5%
Gelir büyüme oranı	13.4%
Gelecekteki özkaynak getirisi	17.7%
Analist kapsamı	Low
Son güncelleme	25 Oct 2024

Gelecekteki son büyüme güncellemeleri

Aarti Drugs Limited Recorded A 9.0% Miss On Revenue: Analysts Are Revisiting Their Models

Feb 01

Recent updates

We Discuss Why Aarti Drugs Limited's (NSE:AARTIDRUGS) CEO Will Find It Hard To Get A Pay Rise From Shareholders This Year

Sep 20

Aarti Drugs (NSE:AARTIDRUGS) Has A Somewhat Strained Balance Sheet

Sep 05

Is Aarti Drugs (NSE:AARTIDRUGS) A Risky Investment?

May 04

Aarti Drugs Limited Recorded A 9.0% Miss On Revenue: Analysts Are Revisiting Their Models

Feb 01

Aarti Drugs (NSE:AARTIDRUGS) Is Due To Pay A Dividend Of ₹1.00

Jan 30

Aarti Drugs' (NSE:AARTIDRUGS) Anemic Earnings Might Be Worse Than You Think

May 17

These 4 Measures Indicate That Aarti Drugs (NSE:AARTIDRUGS) Is Using Debt Reasonably Well

Nov 22

We Take A Look At Why Aarti Drugs Limited's (NSE:AARTIDRUGS) CEO Has Earned Their Pay Packet

Aug 28

Here's Why We Think Aarti Drugs (NSE:AARTIDRUGS) Is Well Worth Watching

Aug 19

Is Aarti Drugs Limited (NSE:AARTIDRUGS) Expensive For A Reason? A Look At Its Intrinsic Value

May 17

Here's Why I Think Aarti Drugs (NSE:AARTIDRUGS) Is An Interesting Stock

Apr 04

Does Aarti Drugs (NSE:AARTIDRUGS) Have A Healthy Balance Sheet?

Mar 17

Aarti Drugs Limited's (NSE:AARTIDRUGS) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock?

Mar 02

Aarti Drugs' (NSE:AARTIDRUGS) Wonderful 432% Share Price Increase Shows How Capitalism Can Build Wealth

Jan 07

If You Like EPS Growth Then Check Out Aarti Drugs (NSE:AARTIDRUGS) Before It's Too Late

Dec 23

Aarti Drugs (NSE:AARTIDRUGS) Seems To Use Debt Quite Sensibly

Dec 08

Aarti Drugs Limited's (NSE:AARTIDRUGS) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock?

Nov 23

How Much Of Aarti Drugs Limited (NSE:AARTIDRUGS) Do Insiders Own?

Nov 08

Kazanç ve Gelir Büyüme Tahminleri

NSEI:AARTIDRUGS - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (INR Millions )
Tarih	Gelir	Kazançlar	Serbest Nakit Akışı	Faaliyetlerden Nakit	Avg. Analist Sayısı
3/31/2027	32,612	3,107	1,443	2,943	1
3/31/2026	28,695	2,467	773	2,273	1
3/31/2025	24,560	1,561	1,315	3,315	1
9/30/2024	23,796	1,522	1,019	3,082	N/A
6/30/2024	24,228	1,568	N/A	N/A	N/A
3/31/2024	25,286	1,714	1,326	3,589	N/A
12/31/2023	26,510	1,802	N/A	N/A	N/A
9/30/2023	27,090	1,802	1,213	3,171	N/A
6/30/2023	27,552	1,794	N/A	N/A	N/A
3/31/2023	27,161	1,663	-315	1,333	N/A
12/31/2022	26,679	1,656	N/A	N/A	N/A
9/30/2022	26,387	1,872	-836	700	N/A
6/30/2022	25,306	1,910	N/A	N/A	N/A
3/31/2022	24,886	2,050	-816	704	N/A
12/31/2021	22,961	2,014	N/A	N/A	N/A
9/30/2021	21,916	2,111	137	1,322	N/A
6/30/2021	21,901	2,438	N/A	N/A	N/A
3/31/2021	21,548	2,804	667	1,550	N/A
12/31/2020	21,027	2,876	N/A	N/A	N/A
9/30/2020	20,459	2,474	1,338	2,070	N/A
6/30/2020	19,453	2,044	N/A	N/A	N/A
3/31/2020	18,061	1,414	2,028	2,507	N/A
12/31/2019	18,156	1,100	N/A	N/A	N/A
9/30/2019	17,222	1,031	N/A	N/A	N/A
6/30/2019	15,921	888	N/A	N/A	N/A
3/31/2019	15,609	898	688	1,431	N/A
12/31/2018	14,136	863	N/A	N/A	N/A
9/30/2018	13,689	887	N/A	N/A	N/A
6/30/2018	13,407	943	N/A	N/A	N/A
3/31/2018	12,436	823	N/A	698	N/A
12/31/2017	11,592	790	N/A	N/A	N/A
9/30/2017	11,340	735	N/A	N/A	N/A
6/30/2017	11,569	721	N/A	N/A	N/A
3/31/2017	11,952	818	N/A	1,748	N/A
12/31/2016	12,102	785	N/A	N/A	N/A
9/30/2016	11,856	776	N/A	N/A	N/A
6/30/2016	11,431	713	N/A	N/A	N/A
3/31/2016	11,349	687	N/A	1,333	N/A
12/31/2015	11,101	686	N/A	N/A	N/A
9/30/2015	11,047	744	N/A	N/A	N/A
6/30/2015	11,180	774	N/A	N/A	N/A
3/31/2015	10,943	773	N/A	1,046	N/A
12/31/2014	10,868	807	N/A	N/A	N/A
9/30/2014	10,490	721	N/A	N/A	N/A
6/30/2014	10,109	662	N/A	N/A	N/A
3/31/2014	9,699	608	N/A	954	N/A
12/31/2013	9,083	526	N/A	N/A	N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: AARTIDRUGS 'nin tahmini kazanç büyümesi (yıllık 31.5% ) tasarruf oranının ( 6.7% ) üzerindedir.

Kazançlar ve Piyasa: AARTIDRUGS şirketinin kazançlarının (yıllık 31.5% ) Indian pazarından (yıllık 18.1% ) daha hızlı büyümesi öngörülüyor.

Yüksek Büyüme Kazançları: AARTIDRUGS şirketinin kazançlarının önümüzdeki 3 yıl içerisinde önemli ölçüde artması bekleniyor.

Gelir ve Pazar: AARTIDRUGS şirketinin gelirinin (yıllık 13.4% ) Indian pazarından (yıllık 10.5% ) daha hızlı büyümesi öngörülüyor.

Yüksek Büyüme Geliri: AARTIDRUGS şirketinin gelirinin (yıllık 13.4% ) yıllık 20% oranından daha yavaş büyümesi öngörülüyor.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: AARTIDRUGS 'nin Özsermaye Getirisi'nin 3 yıl içinde düşük olması tahmin ediliyor ( 17.7 %).

Büyüyen şirketleri keşfedin

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2024/12/24 17:37
Gün Sonu Hisse Fiyatı	2024/12/24 00:00
Kazançlar	2024/09/30
Yıllık Kazançlar	2024/03/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Buradan daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntıları Github sayfamızda mevcuttur, ayrıca raporlarımızın nasıl kullanılacağına dair kılavuzlarımız ve Youtube'da eğitimlerimiz bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları 'da mevcuttur.

Analist Kaynakları

Aarti Drugs Limited 4 Bu analistlerden 1, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Analist	Kurum
Rashmi Sancheti Shetty	CGS International
Rashmi Sancheti Shetty	Dolat Capital Market Pvt. Ltd.
Kameswari V. S. Chavali	FirstCall Research

Aarti Drugs Gelecekteki Büyüme

Future kriter kontrolleri 4/6

Anahtar bilgiler

Gelecekteki son büyüme güncellemeleri

Aarti Drugs Limited Announces Restoration of Manufacturing Process of Particular Product At T-150 Unit

Aarti Drugs Limited Announces Restoration of Manufacturing Process of Particular Product At T-150 Unit

Price target decreased by 9.4% to ₹562

Price target increased by 22% to ₹578

Aarti Drugs Limited Recorded A 9.0% Miss On Revenue: Analysts Are Revisiting Their Models

Price target decreased by 8.0% to ₹473

Recent updates

Aarti Drugs Limited Announces Restoration of Manufacturing Process of Particular Product At T-150 Unit

Aarti Drugs Limited Announces Restoration of Manufacturing Process of Particular Product At T-150 Unit

Second quarter 2025 earnings released: EPS: ₹3.84 (vs ₹4.29 in 2Q 2024)

Aarti Drugs Limited to Report Q2, 2025 Results on Oct 24, 2024

High number of new directors

Aarti Drugs Limited, Annual General Meeting, Sep 20, 2024

Aarti Drugs Limited, Annual General Meeting, Sep 20, 2024

Aarti Drugs Limited (BSE:524348) announces an Equity Buyback for 665,000 shares, representing 0.72% for INR 598.5 million.

Aarti Drugs Limited to Report Q1, 2025 Results on Jul 26, 2024

Full year 2024 earnings: EPS in line with expectations, revenues disappoint

High number of new directors

Aarti Drugs Limited Announces Executive Cessation

Price target decreased by 9.4% to ₹562

Upcoming dividend of ₹1.00 per share at 0.2% yield

Third quarter 2024 earnings released: EPS: ₹3.99 (vs ₹3.96 in 3Q 2023)

Aarti Drugs Limited Announces Interim Dividend for the Financial Year 2023- 24

Aarti Drugs Limited to Report Q3, 2024 Results on Jan 24, 2024

Second quarter 2024 earnings released: EPS: ₹4.29 (vs ₹4.19 in 2Q 2023)

Now 21% undervalued

Aarti Drugs Limited to Report Q2, 2024 Results on Oct 19, 2023

We Discuss Why Aarti Drugs Limited's (NSE:AARTIDRUGS) CEO Will Find It Hard To Get A Pay Rise From Shareholders This Year

Now 21% undervalued

Aarti Drugs (NSE:AARTIDRUGS) Has A Somewhat Strained Balance Sheet

Aarti Drugs Limited, Annual General Meeting, Sep 26, 2023

Aarti Drugs Limited, Annual General Meeting, Sep 26, 2023

Price target increased by 22% to ₹578

Aarti Drugs Limited (BSE:524348) announces an Equity Buyback for 665,000 shares, representing 0.72% for INR 598.5 million.

First quarter 2024 earnings released: EPS: ₹5.17 (vs ₹3.76 in 1Q 2023)

Aarti Drugs Limited to Report Q1, 2024 Results on Jul 21, 2023

Is Aarti Drugs (NSE:AARTIDRUGS) A Risky Investment?

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Investor sentiment improves as stock rises 20%

Investor sentiment improves as stock rises 17%

Upcoming dividend of ₹1.00 per share at 0.2% yield

Aarti Drugs Limited Recorded A 9.0% Miss On Revenue: Analysts Are Revisiting Their Models

Price target decreased by 8.0% to ₹473

Aarti Drugs (NSE:AARTIDRUGS) Is Due To Pay A Dividend Of ₹1.00

Third quarter 2023 earnings released: EPS: ₹3.96 (vs ₹6.30 in 3Q 2022)

Aarti Drugs Limited Declares Interim Dividend for the Financial Year 2022-23

Aarti Drugs Limited to Report Q3, 2023 Results on Jan 27, 2023

Second quarter 2023 earnings released: EPS: ₹4.19 (vs ₹4.60 in 2Q 2022)

Aarti Drugs Limited to Report Q2, 2023 Results on Oct 20, 2022

Aarti Drugs Limited Appoints Independent Directors

Aarti Drugs Limited to Report Q1, 2023 Results on Jul 27, 2022

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Aarti Drugs Limited, Annual General Meeting, Aug 04, 2022

Aarti Drugs' (NSE:AARTIDRUGS) Anemic Earnings Might Be Worse Than You Think

Aarti Drugs Limited Announces Executive Appointments

Aarti Drugs Limited Announces Executive Appointments

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Now 20% undervalued after recent price drop

Price target decreased to ₹678

Less than half of directors are independent

Price target decreased to ₹678

Investor sentiment improved over the past week

Aarti Drugs Limited Announces Board Changes

Insider recently sold ₹79m worth of stock

Now 21% undervalued after recent price drop

Whole-Time Director recently bought ₹761k worth of stock

Chairman recently bought ₹4.3m worth of stock

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Aarti Drugs Limited to Report Q3, 2022 Results on Jan 31, 2022

Aarti Drugs Limited to Report Q3, 2022 Results on Jan 31, 2022

Now 20% undervalued after recent price drop

Chairman recently bought ₹104k worth of stock

Chairman recently bought ₹15m worth of stock

These 4 Measures Indicate That Aarti Drugs (NSE:AARTIDRUGS) Is Using Debt Reasonably Well

Price target decreased to ₹780

Price target decreased to ₹780